Nephrology · Evidence-Based Practice

Guideline-Directed Medical Therapy
in Chronic Kidney Disease

Enter patient parameters to assess GDMT eligibility, contraindications, and dose adjustments — with and without Type 2 Diabetes.

KDIGO 2024 ADA 2024 KDIGO 2022 Diabetes in CKD ESC 2023

🧬

Patient Profile

Enter values to personalise GDMT assessment

eGFR

ml/min/1.73m² — CKD-EPI 2021

UACR

mg/g (or mg/mmol × 8.84)

Serum K⁺

mEq/L (normal: 3.5–5.0)

SBP

mmHg — standardised office measurement

Type 2 Diabetes Mellitus

Includes glucose-lowering agents with cardiorenal benefit (SGLT2i, GLP-1 RA, Metformin)

T2D Active

All CKD Core GDMT — regardless of T2D status

CKD + T2D Glucose-lowering agents with cardiorenal benefit

Blood Pressure KDIGO 2024 target

Guideline-Directed Medical Therapyin Chronic Kidney Disease